La Jolla Pharmaceutical (LJPC) reports third-quarter loss, beats revenue estimates

La Jolla Pharmaceutical (LJPC) reported quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.43 per share a year ago. These figures are adjusted for one-time items.

This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this drugmaker would post a loss of $0.13 per share when it actually produced earnings of $0.11, representing a surprise of 184.62%.

The company has topped consensus earnings per share estimates twice over the last four quarters.

La Jolla Pharmaceutical, which belongs to the Zacks Medical – Drugs industry, posted revenues of $13.31 million for the quarter ended September 2021, surpassing the Zacks Consensus Estimate by 10.03%. This compares to revenues of $9.07 million a year earlier. The company has surpassed the consensus revenue estimate four times over the last four quarters.

The sustainability of current share price movements based on recently released data and future earnings expectations will depend primarily on management’s commentary following the earnings conference call.

La Jolla Pharmaceutical shares are up 12.6% year to date, while the S&P 500 is up 24.1%.

What’s next for La Jolla Pharmaceutical Company?

While La Jolla Pharmaceutical has underperformed the market this year, investors are wondering: What’s next for this stock?

There are no easy answers to this key question, but one reliable indicator that can help investors address this is the company’s earnings outlook. This includes not only the current consensus earnings expectations for the coming quarter(s), but also how those expectations have changed recently.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings report, the estimate revision trend for La Jolla Pharmaceutical was mixed. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. As such, the stock is expected to perform in line with the market in the near term. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the upcoming quarters and current fiscal year change in the coming days. The current consensus EPS estimate is -$0.02 on $14.09 million in revenue for the coming quarter and $0.51 on $76.39 million in revenue for the current fiscal year.

Investors should be aware that the outlook for the industry can also have a significant impact on stock performance. In terms of the Zacks Industry Rank, Medical – Drugs currently ranks in the bottom 41% of the 250+ Zacks industries. Our research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click to get this free report

La Jolla Pharmaceutical Company (LJPC): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research